SEARCH

SEARCH BY CITATION

References

  • 1
    Nutt JG, Wooten GF. Clinical practice. Diagnosis and initial management of Parkinson's disease. N Engl J Med 2005; 353: 10211017.
  • 2
    Nelson MV, Berchou RB, LeWitt PA. Parkinson's Disease. In: DiPiroJT, TalbertRL, YeeGC, et al, eds. Pharmacotherapy: a pathophysiologic approach. 5th ed. Stamford, CT: Appleton & Lange, 2005: 10891102.
  • 3
    Shoulson I, Oakes D, Fahn S, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension. Ann Neurol 2002; 51: 604612.
  • 4
    Parkinson Study Group. Pramipexole vs. levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004; 61: 10441053.
  • 5
    Widnell K. Pathophysiology of motor fluctuations in Parkinson's disease. Mov Disord 2005; 20(suppl 11): S17S22.
  • 6
    Rosin DL, Hettinger BD, Lee A, Linden J. Anatomy of adenosine A2A receptors in brain: morphological substrates for integration of striatal function. Neurology 2003; 61(suppl 6): S12S18.
  • 7
    Mori A, Shindou T. Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A antagonists. Neurology 2003; 61(suppl 6): S44S48.
  • 8
    Kase H. Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW-6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease. Neurology 2003; 61(suppl 6): S97S100.
  • 9
    Jenner P. Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson's disease. Expert Opin Investig Drugs 2005; 14: 729738.
  • 10
    Lundblad M, Vaudano E, Cenci MA. Cellular and behavioural effects of the adenosine A2A receptor antagonist KW-6002 in a rat model of L-DOPA-induced dyskinesia. J Neurochem 2003; 84: 13981410.
  • 11
    Kanda T, Jackson MJ, Smith LA, et al. Combined use of the adenosine A2A antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol 2000; 162: 321327.
  • 12
    Aoyama S, Kase H, Borrelli E. Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist. J Neurosci 2000; 20: 58485852.
  • 13
    Kanda T, Tashiro T, Kuwana Y, et al. Adenosine A2A receptors modify motor function in MPTP-treated common marmosets. NeuroReport 1998; 9: 28572860.
  • 14
    Hauser RA, Hubble JP, Truong DD, Istradefylline US-001 Study Group. Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD. Neurology 2003; 61: 297303.
  • 15
    Bara-Jimenez W, Sherzai A, Dimitrova T, et al. Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 2003; 61: 293296.
  • 16
    Brooks DJ, Doder M, Osman S, et al. Adenosine A2A receptor occupancy by istradefylline. An [11C]KW-6002 PET study in healthy subjects. Neurology 2005; 64(suppl 1): A235 (Abstract).
  • 17
    Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 1992; 11: 11421146.
  • 18
    Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427442.
  • 19
    Hauser RA, Friedlander J, Zesiewicz TA, et al. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol 2000; 23: 7581.
  • 20
    Fahn S, Elton RL, Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: FahnS, MarsdenCD, CalneDB, GoldsteinM, eds. Recent developments in Parkinson's disease. Vol 2. Florham Park, NJ: Macmillan Health Care Information, 1987: 153163, 293–304.
  • 21
    Pahwa R, Factor SA, Lyons KE, et al. Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66: 983995.
  • 22
    Golembiowska K, Dziubina A. Striatal adenosine A2A receptor blockade increases extracellular dopamine release following l-DOPA administration in intact and dopamine-denervated rats. Neuropharmacology 2004; 47: 414426.
  • 23
    O'Neill M, Brown VJ. The effect of the adenosine A2A antagonist KW-6002 on motor and motivational processes in the rat. Psychopharmacology 2006; 184: 4655.
  • 24
    Ikeda K, Kurokawa M, Aoyama S, Kuwana Y. Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease. J Neurochem 2002; 80: 262270.